Judy Vong

Judy joined Janux Therapeutics in March 2026 and is responsible for leading global regulatory strategy and quality assurance across the company’s clinical-stage oncology and autoimmune programs. Prior to joining Janux, Judy served as Vice President, Head of Regulatory Affairs at A2 Biotherapeutics, where she led regulatory strategy for multiple cell therapy programs in solid tumors and supported four successful IND submissions. Earlier at Amgen, she held roles of increasing responsibility, serving as global regulatory lead for early- and late-stage programs, including the AML bispecific portfolio, Enbrel, and Vectibix, and contributing to multiple product approvals and lifecycle management activities. Judy brings extensive experience in oncology, cell therapy, combination products, and companion diagnostics, with deep expertise in global regulatory strategy, health authority engagement, and cross-functional leadership.

Judy holds a Master of Science in Regulatory Science from the University of Southern California and a Bachelor of Science in Applied Ecology from the University of California, Irvine.